Is Insmed (INSM) Cheap After Strong Revenue And Higher 2026 Guidance?

Insmed (INSM) is back in focus after quarterly results showed stronger than expected revenue, driven by BRINSUPRI and ARIKAYCE. The company also reported higher full year 2026 guidance and new regulatory milestones.

The recent beat on third quarter revenue and raised 2026 guidance has shifted sentiment quickly around Insmed, with a 20.6% 7 day share price return and a 14.2% 90 day share price gain contrasting with a year to date share price decline of 36.4% and a 1 year total shareholder return loss of 40.6%. At the same time, the 3 year total shareholder return of about 4.5x and 5 year total shareholder return above 3x point to a story where long term holders have still fared well despite this year’s volatility.

Scan how other respiratory and rare disease biotechs with meaningful revenue and balance sheet strength are trading by checking the hand picked list of solid balance sheet and fundamentals (25 results) alongside Insmed's latest move.

After a rally like this on stronger BRINSUPRI and ARIKAYCE trends, Insmed now poses a harder question: Do the current risks and cash burn still justify the valuation the market is putting on it?

Most Popular Narrative: 43% Undervalued

Insmed last closed at $112.58, while the most followed narrative framework anchors fair value closer to $196.14. The gap investors are debating is how much of the respiratory and pipeline story is already embedded in that share price.

The planned growth of a global respiratory franchise built around shared pulmonology call points for BRINSUPRI, ARIKAYCE and TPIP, together with guidance for combined peak sales of more than $14b from these three assets, is intended to drive higher margin specialty pharma style earnings over time.

See why 22 investors see Insmed as 43% undervalued.

Result: Fair Value of $196.14 (UNDERVALUED)

Still, the Insmed narrative can break if the European BRINSUPRI rollout stays constrained by reimbursement hurdles, or if bronchiectasis diagnoses in COPD and asthma patients scale more slowly than analysts assume.

Find out about the key risks to this Insmed narrative.

Next Steps

Sentiment on Insmed has swung quickly in this piece, so move fast to cut through the noise and test the balance of risks and upside yourself by reviewing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Insmed?

If Insmed has you rethinking your watchlist, do not stop there. Use the tools below to pressure test your next moves and spot opportunities early.

• Target resilience first and scan for companies that hold up under pressure with a 30 resilient stocks with low risk scores. This tool is built to highlight sturdier balance sheets and steadier track records.
• Hunt for pricing gaps and compare Insmed with a broader field of 29 high quality undervalued stocks that screen for quality, cash generation and balance sheet support.
• Find potential early movers by checking a curated pool of 18 high quality undiscovered gems that filters for under-followed businesses with stronger fundamentals than their current pricing suggests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com